The Effects of Neuraminidase Inhibitor Oseltamivir in Patients With Chronic Heart Failure
Status:
Recruiting
Trial end date:
2024-01-25
Target enrollment:
Participant gender:
Summary
Heart failure (HF) is a complex syndrome with increasing incidence and high rates of
mortality and hospitalization. Although inhibitors of angiotensin converting enzyme (ACE),
β-blockers and aldosterone-receptor blockers have improved the treatment of heart failure,
mortality of HF remains unacceptably high.
Recently, we identified a key metabolite N-acetylneuraminic acid (Neu5Ac) increased in the
plasma of patients with heart failure. Also, elevated plasma Neu5Ac, independent of other
traditional risk factors, is associated with poor prognosis in patients with HF in long-term
follow up. Neu5Ac levels, the most common sialic acid in mammals, generated from sialylated
glycoconjugates by neuraminidase. Neu5Ac and its regulatory enzyme neuraminidase play a key
role in heart failure. We found neuraminidase inhibitor could reduce Neu5Ac levels and
improve heart failure in mice model, providing opportunity for a novel therapeutic strategy
in HF. Neuraminidase inhibitor oseltamivir is also an old anti-influenza drug. Using
oseltamivir may be a new therapeutic strategy in heart failure.
Based on above information, we designed the randomized, open-label, blank-controlled study in
patients with chronic HF to receive either oseltamivir or placebo, in addition to standard HF
therapy to Identify the effect of oseltamivir on serum Neu5Ac level in patients with heart
failure and assess the clinic outcomes of level in patients with heart failure using
oseltamivir.